- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Formed in 2001 in Atlanta, Georgia, the approach was originally based on preclinical work done by Harriet Robinson from 1992 to 2002. In 2002, laboratory space, equipment and personnel were acquired and work on an HIV-1 vaccine development plan began. In May 2006, human clinical trials of the drug began. The company has previously worked on developing vaccines for Marburg, Lassa Fever, Ebola, Zika and COVID-19. Currently, the company is focused on developing their GEO-MVA platform for mpox and smallpox, with plans to initiate a Phase 3 immunobridging trial in the second half of 2026.
In January 2020, the company announced initiation of efforts to develop a vaccine against novel coronavirus disease (COVID-19) caused by the SARS-CoV-2 coronavirus. [ citation needed ] The GeoVax program has been added to the "Draft Landscape of COVID-19 Candidate Vaccines" by the World Health Organization.
On September 25, 2020, GeoVax closed an underwritten public offering, raising gross proceeds of $12.8 million. Concurrent with the offering, GeoVax common stock began trading on The Nasdaq Capital Market under the symbol "GOVX".
Recently, the company began collaborating with Emory University on the development of a therapeutic vaccine for human papillomavirus (HPV) infection, with a specific focus on head and neck cancer (HNC). [ citation needed ]